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RESEARCH ARTICLE
Reduced pain perception in children 
and adolescents with ADHD is normalized 
by methylphenidate
Nicole Wolff1*, Katya Rubia2, Hildtraud Knopf3, Heike Hölling3, Julia Martini1, Stefan Ehrlich1 and Veit Roessner1
Abstract 
Background: The present study examined pain perception in children and adolescents with ADHD and the interac‑
tion between pain perception and the administration of methylphenidate (MPH) in order to generate hypotheses 
for further research that will help to clarify the association between ADHD diagnosis, MPH treatment and pain 
perception.
Methods: We included 260 children and adolescents of the “German Health Interview and Examination Survey for 
Children and Adolescents” (KiGGS) and analyzed parent’s assessments of children’s pain distribution and pain percep‑
tion, as well as the influence of MPH administration on pain perception in affected children and adolescents.
Results: Pain perception was associated with ADHD and MPH administration, indicating that children and adoles‑
cents suffering from ADHD without MPH treatment were reported to have lower pain perception compared to both, 
healthy controls (HC) and ADHD patients medicated with MPH.
Conclusion: We suggest that reduced pain perception in children and adolescents with ADHD not medicated with 
MPH may lead to higher risk tolerance by misjudgments of dangerous situations, expanding the importance of MPH 
administration in affected children and adolescents.
Keywords: ADHD, Methylphenidate, Pain, Opioid system, Dopamine
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Background
Attention deficit hyperactivity disorder (ADHD) is char-
acterized by the core symptoms of inattention, hyper-
activity and impulsivity [1] and has a higher prevalence 
(OR = 4.80) among boys compared to girls [2, 3]. Neu-
ropsychological dysfunctions in ADHD are a matter of 
ongoing debate, emphasizing deficits e.g. in response 
inhibition, vigilance, timing and working memory [4–
6]. Neural pathways underlying these deficits point to 
deficits within frontal-subcortical catecholaminergic 
networks, involving dopaminergic and noradrenergic 
innervation [1, 5]. Hence, deficits in dopaminergic neuro-
transmission seem to be highly relevant for the neurobi-
ology and therefore targets of medication of ADHD.
Low-dose psychostimulants, including methylpheni-
date (MPH) and amphetamines are the most widely used 
medications for ADHD [7]. MPH has been shown to sub-
stantially reduce core symptoms of inattention, hyperac-
tivity and impulsivity in up to 70 % of affected children [8, 
9]. However, there are also negative effects of MPH e.g. 
on sleep behavior, i.e. some authors found MPH treat-
ment associated sleep-onset difficulties in patients with 
ADHD of all ages [10, 11]. Despite consistent evidence 
that low doses of MPH influence dopaminergic deficits in 
the brain [1, 12], neural mechanisms underlying its clini-
cal action are not entirely understood at present [12].
Growing evidence suggests that dopamine is involved 
not only in ADHD core symptoms but also in other 
perceptive deficits, such as color perception [13], time 
perception [6, 14, 15] and pain perception [16]. Further-
more, the dopamine system is also closely interrelated 
with the opioid system, which plays a crucial role in pain 
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perception as well as reward and motivation [17]. The 
opioid and dopamine systems interact closely in their 
mediation of reward and motivation, which have been 
shown to be abnormal in ADHD [18]. In addition, there 
is emerging evidence that the opioid system is associated 
with impulsiveness in animals and humans [19] and with 
the mechanism of action of stimulant medication [20, 
21]. Given the close interaction between these two sys-
tems, evidence for associations between the opioid sys-
tem and both ADHD and stimulant mechanism of action, 
raises the question whether pain perception that is medi-
ated by the opioid system may also be altered in ADHD.
In fact, in daily clinical care altered pain perception, 
particularly in younger children with ADHD, has often 
been observed. For example, an association between 
growing pain and childhood restless leg syndrome was 
observed, and it was shown that this effect was more 
often observed in children with ADHD as compared to 
controls [22].
However, to the best of our knowledge, only two stud-
ies examined pain perception in children with ADHD 
[23, 24]. Scherder et al. [23] tested pain perception in 50 
children and adolescents with ADHD, their unaffected 
siblings and HC [23], assessed through the children’s 
pain inventory. The study found no differences in pain 
perception in children and adolescents with and without 
ADHD. However, the 35 unaffected siblings of children 
and adolescents with ADHD reported reduced intensity 
and emotionality of past pain experiences compared to 
the unrelated HC [23]. The authors suggested that the 
long-term exposure of non-affected siblings to the “phys-
ical aggressiveness of their affected siblings” might have 
resulted in the observation of lower pain perception in 
the non-affected siblings [23]. Unfortunately, medica-
tion status of children and adolescents with ADHD dur-
ing the period when pain experience was assessed was 
not considered which might have masked possible group 
differences in pain perception. In the second part of the 
study, children and adolescents with ADHD and their 
unaffected siblings gave blood for genetic analysis and 
were asked to assess the intensity and emotionality of 
perceived pain after the venipuncture. For this analysis, 
children and adolescents were requested to abstain from 
taking medication for at least 48  h. Children and ado-
lescents with ADHD compared to non-affected siblings 
reported reduced pain perception. The second study, 
inducing experimentally pain in adolescents with ADHD 
[24] analyzed whether there is an association between 
subjective and physiological responses to pain and the 
presence of a comorbid conduct disorder (CD) in ado-
lescents with ADHD. They analyzed adolescents with 
pure ADHD in comparison to adolescents with ADHD 
plus CD and measured pain perception through thermal 
heat on the skin of the palm of the hand. In addition, they 
collected the skin conductance level (SCL) and ques-
tionnaire reports on self-reported pain threshold and 
pain tolerance times. It was observed that although ado-
lescents with ADHD plus CD vs adolescents with pure 
ADHD reported significantly increased pain threshold 
time and tolerance, the physiological response and SCL 
was similar in both groups. It was thus emphasized that 
it is important to consider comorbidities of ADHD when 
developing interventions. Moreover it was argued that 
it is important to bear in mind the interaction between 
aggression, antisocial behaviour, conduct disorder, and 
pain in the ADHD population [24].
Two further studies investigated pain perception in 
adults with ADHD, both finding enhanced pain [16, 25]. 
One study reported increased pain perception in a small 
sample of 25 adults with ADHD relative to 23 controls, 
assessed via a numerical pain rating scale, as well as more 
widespread pain, analyzed using a so-called pain draw-
ing procedure [26]. Using a motor function neurologi-
cal assessment (MFNU) in addition, they observed also 
that adults with ADHD compared to controls had motor 
inhibition problems and heightened muscle tone e.g. 
in the latissimus dorsi and calf muscles [25]. Pain loca-
tion and pain levels were furthermore positively corre-
lated with the total score on the MFNU, indicating that 
the pain reported in the ADHD group might be a con-
sequence of their muscle tone dysregulation and motor 
inhibition problems [25]. However, most patients were 
responders to stimulant medication and the study did 
not state how many or whether any of the patients were 
medication-naive.
In the other study on pain perception in 30 adults with 
ADHD, pain was experimentally induced by 1  °C cold 
water. Adults with ADHD were more sensitive to pain 
[16] but pain perception was modified by MPH: adults 
with ADHD without MPH medication displayed lower 
pain threshold, i.e. a shorter interval from cold water 
exposure to the beginning of pain, and reduced pain 
tolerance, i.e. shorter interval participants can bear up 
against pain, in comparison to both, participants with 
ADHD medicated with MPH and HC.
In summary, pain perception seems to be altered in 
ADHD and to be influenced by the administration of 
MPH. Interestingly, although direct associations have 
not been investigated at this point, it can also be assumed 
that alterations in pain perception in ADHD may also 
be treated by the help of Neurofeedback [27, 28]. Here, 
frequencies in the alpha (about 10  Hz) and in the delta 
band (about 1–3 Hz) have been shown to influence mus-
cle contraction as well as pain perception, which might 
also help to normalize pain perception in ADHD. Simi-
larly, training of mindfulness has been associated with 
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improvements in self-regulation of attention in ADHD 
[29] as well as with increased body perception. Thus a 
range of mind–body approaches may also be used in the 
management of altered pain perception [30]. All these 
treatments may thus be of benefit in the treatment of 
ADHD (both reduction of core symptoms and improve-
ment of pain perception).
However, studies on pain perception have been 
inconclusive, with one study in children reporting 
no differences in past pain but reduced perception of 
induced pain between children with ADHD and HC 
[23], one study in adolescents comparing adolescents 
with pure ADHD and those with ADHD and comor-
bid CD reported similar physiological pain perception 
but decreased reported pain perception in adolescents 
with ADHD and CD as compared to adolescents with 
pure ADHD [24] and the two adult studies reporting 
enhanced pain perception [16, 25], which furthermore 
appeared to be modified/normalized by MPH [16]. The 
conflicting findings may be due to low power in small 
sample sizes or differential pain perception in different 
age groups of ADHD patients. However conflicting find-
ings between studies could also be a result of differences 
in applied diagnostic criteria (DSM IV vs DSM 5 vs ICD 
10). It has for example been observed that the manifesta-
tion of ADHD subtypes differs (i) between adolescents 
and adults and (ii) through the application of different 
diagnostic systems. Moreover, the diagnosis of ADHD as 
well as common comorbidities, for example autism spec-
trum disorders (ASD) differs depending on the diagnos-
tic system used.
The purpose of the present study was to generate 
hypotheses for further research that will clarify the asso-
ciation between ADHD diagnosis, MPH treatment and 
pain perception. Thus we analyzed this research question 
in a large, representative sample of German children and 
adolescents. Although altered pain perception has been 
observed recurrently in children with ADHD in clini-
cal praxis, to the best of our knowledge, no large-scale 
study has tested (1) pain distribution and pain perception 
in children with ADHD compared to that of HC and (2) 
the effect of MPH treatment on pain perception differ-
ences. Since alterations in pain perception, the mode of 
action of MPH and the neurochemical changes underly-
ing ADHD are all linked to dopaminergic deficits in the 
brain, we hypothesized that pain perception would differ 
between children and adolescents with ADHD relative to 
HC and between medicated and non-medicated patients 
with MPH. Furthermore, given evidence that age and 
gender have an impact on pain perception [31–33], we 
also tested the effects of these two variables on potential 
group differences.
Methods
The present study analyzed data from the German Health 
Interview and Examination Survey for Children and 
Adolescents called “KiGGS’’. KiGGS represents a nation-
wide, representative cross-sectional health interview 
and examination survey conducted in Germany from 
May 2003 until May 2006 by the Robert Koch Institute 
(RKI). The KiGGS study surveyed 17,641 children and 
adolescents aged from birth to 17  years from 176 cities 
and municipalities across Germany. The children and 
adolescents were physically examined and the father and/
or mother (depending on which parent accompanied the 
child) as well as children over the age of 11  years com-
pleted a questionnaire covering psychological and social 
assessment. The study is fully compliant with the Decla-
ration of Helsinki and was approved by the ethics com-
mittee at the University Hospital—Charité in Berlin and 
the Federal Office for the Protection of the Data. Signed 
informed consent was obtained from the primary car-
egivers of all study participants and also from all ado-
lescents of 14 years or above. KiGGS consisted of a core 
survey (on which we access in the present study) and five 
additional subsample modules (on which we do not fur-
ther refer here). Within KiGGS several self-administered 
questionnaires collecting data according to i.e. physical 
health, behavioral and emotional problems, social deter-
minants of health, health-related behavior, health care 
service utilization and socio demographics were designed 
by the RKI. More details according to further objectives, 
design and measurements of KiGGS were reported else-
where [34].
We focused on participants with available information 
regarding ADHD diagnosis, MPH medication, informa-
tion about pain during the last 3 months, as well as “pain 
perception” (see the column “pain perception sample” in 
Table 1). Sixty-five participants met all these criteria (see 
participants of the category “ADHD with MPH” within 
the pain perception sample) and were compared to sixty-
five unmedicated ADHD participants randomly selected 
from the remainder of the sample (n = 115). In addition, 
a similarly sized age-matched healthy control group with-
out ADHD diagnosis and without any medication was 
randomly selected out of the remaining pain perception 
sample (n = 2687). In sum, the analyzed group (refer to 
the column with the heading “study sample” in Table 1) 
contains of 260 participants (50.0 % ADHD, 25.0 % MPH 
medicated, 70.8 % male) in the age range between 7 and 
10 years (47.7 %), 11–13 years (31.5 %) and 14–17 years 
(21.2  %). Among those diagnosed with ADHD, 98 
(75.4 %) were male and 32 (24.6 %) were female. For more 
details concerning the substitution of our sample, see 
Table 1.
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ADHD diagnosis Participants were allocated to the 
ADHD group, if they had ever been diagnosed with 
ADHD. For this purpose, parents were asked, whether 
their child was diagnosed with ADHD. If they answered 
“yes” it was further specified whether ADHD was diag-
nosed by a physician or psychologist. For an estimation 
of the validity of the parental answer, symptomatic infor-
mation was correlated with the scale “hyperactivity” of 
the strengths and difficulties questionnaire (SDQ, Cron-
bach’s α  =  0.78) [35]. In addition, a ROC analysis with 
the hyperactivity scale of the SDQ as explanatory variable 
and the diagnosis question as criterion was applied and 
revealed a AUC (region under the curve) of =0.86. [35]. 
Finally, although a clarified subtype specification, like 
in DSM IV [36, 37] into a predominantly hyperactive-
impulsive type (ADHD-H), predominantly inattentive 
type (ADHD-I), and combined type (ADHD-C) took not 
place, parents of ADHD children were asked to specify 
whether ADHD or ADD was diagnosed.
MPH medication Data on the current intake of medi-
cation were collected by a standardized interview con-
ducted by a physician. More information concerning 
applied methods, prevalence and determinants of ADHD 
medication can be found in Knopf [38] as well as Knopf 
et al. [3].
Pain distribution and pain perception To assess pain 
distribution and perception, parents as well as chil-
dren and adolescents were asked about pain during the 
last 3  months. More specifically if children were in the 
age between 7 and 10  years parents were asked about 
their children’s pain, if children and adolescents were in 
the age range between 11 and 17 years they were asked 
directly about their own pain perception. If partici-
pants answered the question with “yes”, they were asked: 
“Which pain could be characterized as the “main pain”? 
The “main pain” (e.g. headache, back pain, ear pain, eye 
pain, stomach pain, arm or leg pain, toothache, etc.) 
needed to be specified according to “pain perception” 
(0 = hardly noticeable pain to 100 = maximum imagina-
ble pain). For the purpose of this study we created a new 
variable “pain perception”, which contains both informa-
tion the data from the parents (if children were younger 
than 11  years) as well as the data from children and 
adolescents their self (if children and adolescents were 
between 11 and 17 years). For more information on the 
measurement of pain via the KiGGS Data please refer to 
[39]. However, please note that the assessment of pain 
perception was measured via self-constructed question-
naires by the RKI, indicating that information according 
to validity or reliability of the measurement is missing.
Statistical analyses First, Chi square tests were con-
ducted to analyze possible differences in sample charac-
teristics (age and gender) between the three participant 
groups (ADHD with MPH, ADHD without MPH, HC). 
Second, Chi square tests were conducted to analyze the 
association between (a) “participant group” (ADHD 
with MPH, ADHD without MPH, HC) and the “type 
of main pain”, (b) “age” (7–10, 11–13, 14–17  years) and 
the “type of main pain” and (c) “gender” (male/female) 
and the “type of main pain”. Last, an analysis of covari-
ance (ANCOVA) with the dependent variable “pain per-
ception”, the independent variable “participant group” 
(ADHD with MPH, ADHD without MPH, HC) and the 
cofactors “age” (7–10, 11–13, 14–17 years) and “gender” 
(male, female) was conducted and Bonferroni corrected. 
All statistical analyses were conducted using SPSS 22 
(SPSS, Inc., Chicago, Il, USA).
Results
Sample characteristics (see Table  1). Chi Square test 
analyzing the association between “participant group” 
(ADHD with MPH, ADHD without MPH, HC) and 
“age” (7–10  years, 11–13  years, 14–17  years) in the 
study sample revealed no significant effect (χ2 =  0.573, 
df =  4, p =  0.966). In addition a similar analysis in the 
study sample between “participant group” and “gender” 
(female, male) revealed no significant effect (χ2 =  3.27, 
df = 2, p = 0.195). This showed no differences related to 
“age” or “gender” between the three participant groups, 
included in our study sample.
Type of main pain Chi Square test analyzed the asso-
ciation between “participant group”, “age”, “gender” and 
the “type of main pain”. This analysis revealed no signifi-
cant effects (all p  >  0.05), indicating that group reports 
of main pain type were independent of ADHD diagnosis, 
use of MPH medication, age or gender.
Pain perception (see Fig.  1). The analysis revealed a 
main effect for “participant group” on “pain percep-
tion” (F[2234]  =  4.62, p  =  0.011, η2  =  0.039). Post 
hoc t-tests indicate that children and adolescents 
with ADHD without MPH reported lower pain per-
ception (M  =  41.69,  ±  21.27 SD) compared to HC 
(M = 50.2, ± 23.51 SD; t[193] = 2.46, p = 0.015) and com-
pared to children and adolescents with ADHD and MPH 
(M = 51.17, ± 21.87 SD; t[128] = −2.51, p = 0.014). In 
addition, no significant differences in “pain perception” 
were observed between children and adolescents with 
ADHD and MPH and HC (t[193] = −0.28, p =  0.782). 
Since the variable “pain perception” represents a com-
bined variable of analyzed data from children and ado-
lescents (in the age between 11 and 17 years) as well as 
from parents (in the age between 7 and 10  years), we 
analyzed data separately as well. The analysis on paren-
tal (F[2152] = 4.35, p = 0.015, η2 = 0.055) as well as on 
children’s (F[2105] = 8.97, p = 0.003, η2 = 0.079) infor-
mation revealed a significant main effect for “participant 
Page 6 of 10Wolff et al. Child Adolesc Psychiatry Ment Health  (2016) 10:24 
group” on “pain perception”. Both main effects report the 
same finding, as was observed in the analysis of the com-
bined pain perception variable.
Discussion
The present study examined alterations in pain percep-
tion and pain distribution in children and adolescents 
with ADHD relative to HC and the impact of MPH on 
these.
Pain distribution was similar among the three groups, 
indicating that no specific kind of somatic pain was pre-
dominant in any of the three participant groups. How-
ever, children and adolescents with ADHD without MPH 
reported lower pain perception compared to both, HC 
and stimulant-medicated children and adolescents with 
ADHD. Although the present study should be regarded 
as a first step, in which collected and analyzed data stem 
from questionnaires instead of a controlled experimental 
design, they offer a hint into the direction that MPH may 
enhance abnormally reduced pain perception in children 
and adolescents with ADHD up to the level of HC.
To our knowledge, this is the first large-numbered study 
on reduced pain perception in children with ADHD. The 
findings help to extend findings from a previous pilot 
study in children with ADHD that found reduced percep-
tion of induced pain [23] as well as findings of a study on 
pain perception in pure ADHD vs ADHD with comor-
bid CD [24]. However, they are not in line with the two 
studies testing induced pain perception via thresholds in 
adults with ADHD who found enhanced pain perception 
in controlled experimental settings [16, 25]. Furthermore, 
in the study of Treister et al. [16], MPH also seemed to 
normalize pain perception, however, in contrast to our 
study findings, by reducing the elevated pain percep-
tion up to the level of HC. These differences in findings 
between pediatric and adults studies could be explained 
by differences in the methodology of assessing pain per-
ception, which in our study were assessed using parent-/
child-rated questionnaires of their child’s/their own pain 
over the last 3 months while in the two adult studies they 
were tested experimentally by inducing pain [16, 25]. In 
fact, the mentioned pilot study in children [23] found no 
differences in questionnaire-assessed pain perception in 
children with ADHD but in the perception of induced 
pain, suggesting that the two methodologies assess differ-
ent aspects of pain perception and are not directly com-
parable. In addition, external ratings (parent ratings) of 
the child’s pain may not be accurate given that pain is a 
subjectively felt perception and difficult to rate externally 
[40, 41]. However, our additional analysis, testing both 
responses (parents as well as children and adolescents) 
separately revealed identical effects. Still, measures of 
induced pain perception may potentially be more objec-
tive and sensitive than external ratings of someone else’s 
pain [42]. Accordingly the results of the present study 
should be regarded as a first step, although the results 
stem from a huge representative sample of German chil-
dren and adolescents and could be used for generating 
more specific hypotheses for further research. In addi-
tion, recruitment is quite different between an epidemio-
logical sample where parents mainly decide to participate 
and a smaller sample of clinically referred adults seeking 
help for their ADHD and participating in an experimen-
tal study. One possible explanation might be that those 
in the adult ADHD sample were generally less patient 
and more introspective than their HCs. If so, they might 
have been more impatient and less motivated to toler-
ate their experimentally induced pain, something that 
could have been improved by MPH. In addition, adults 
with ADHD have shown further characteristics, such as 
reduced educational performance, reduced attainment 
in workplace functioning as well as in the occupational 
attainment, increased risk for substance dependence 
and abuse, driving risks and irregularities in marital 
and interpersonal relations [43]. These specifics in com-
bination with increased scores on avoidant, histrionic, 
narcissistic, negativistic, and self-defeating personality 
scales [44] may also explain the increased pain percep-
tion found in adults with ADHD. A difference between 
the existing studies that has been shown to impact on 
pain perception in general is age [45]. As in the rest of the 
population, adults with ADHD may have a different per-
ception of pain than children with ADHD. Moreover, as 
stated in the introduction, differences in reported results 
of pain perception in ADHD may also rely on differences 
Fig. 1 Differences in pain perception (0 = hardly noticeable pain to 
100 = maximum imaginable pain) in children and adolescents with 
ADHD without MPH treatment (n = 65), children and adolescents 
with ADHD with MPH treatment (n = 65) and HC (n = 130). All chil‑
dren and adolescents were in the age range between 7 and 17 years. 
Error bars depict standard errors of the mean. The asterisk represents a 
significant difference on the p <.05 level
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in applied diagnostic systems (IDC 10, DSM IV and DSM 
V) including the associated underestimation and partly 
non-consideration of comorbidities like ASD. Interest-
ingly, in accordance to our findings on ADHD, an impor-
tant feature of ASD is heightened or reduced sensitivity 
for pain [46, 47], pointing to differences between study 
results on pain perception whether participants with 
pure ADHD or with comorbid disorders like ASD [46, 
47] or CD [24] were included in the sample.
Medication may potentially also be a confound, given 
that we found medication to upregulate reduced pain 
perception. Clinically recruited adults still suffering from 
ADHD are a specific subgroup of persisting ADHD and 
also have typically had a longer exposure to stimulant 
medication. This was in particular the case in the study of 
Stray [25] who recruited responders to stimulant medi-
cation only. It is possible that long-term stimulant medi-
cation over years in adults enhances the pain threshold 
in ADHD to the extent to elevate it to abnormally high 
levels.
The findings of reduced pain perception and its mod-
ulation by stimulant medication are also interesting in 
view of recent evidence that the opioid system is impli-
cated in impulsiveness [19] and in the mechanism of 
action of stimulant medication [20, 21].
The opioid and dopamine systems interact very closely 
and are both crucially related to reward and motivation 
[17] which has been found to be abnormal in ADHD 
[18]. The opioid system has recently been found to be 
associated with impulsive behaviors such as inhibitory 
control and impulsive choice and higher opioid systems 
have been observed in healthy adults with impulsiveness 
traits [19]. In line with this, naltrexone, an opioid antago-
nist, improves self-control in impulsive disorders [48] 
and modulates brain regions implicated in motivational 
impulsiveness [49] that are typically abnormal in ADHD 
during reward-related processes such as ventral striatum 
and ventromedial orbitofrontal cortex [50]. An implica-
tion of the opioid system in impulsiveness hence may well 
also be associated with abnormal pain perception given 
the involvement of the opioid system in pain perception. 
The association with higher opioid levels in adults with 
impulsiveness behaviors [19] is in the same direction 
with our finding of reduced pain thresholds in children 
with ADHD. It can thus be speculated that reduced pain 
perception in unmedicated children with ADHD may be 
due to abnormally high opioid levels. However, in regard 
to the applied methods of our study such considerations 
should be taken with care, and need further experimental 
examination.
Furthermore, dopamine agonists such as ampheta-
mines have been shown to release opioids in positron 
emission tomography studies in healthy adults [20, 21]. 
The findings suggest that stimulants do not work exclu-
sively via the catecholamine systems but also via the opi-
oid system. It also implies that the opioid system may be 
abnormal in ADHD, given the effectiveness of stimulants 
on ADHD behaviors. If opioids are released after stimu-
lant medication in ADHD, like in healthy adults, then this 
could also explain the underlying mechanism of action of 
the modulation of pain perception in medicated ADHD 
children relative to unmedicated ones. In fact, stimu-
lants enhance dopamine release in ADHD patients more 
than in healthy subjects [51], which would synergistically 
also enhance opioid levels, even if it was a purely down-
stream effect, which could then modulate the abnormally 
reduced pain perception. Considering these effects of 
psychostimulants on the opioid system, it is conceivable 
that long-term stimulant medication alters pain percep-
tion in ADHD subjects, which may well be different in 
adults who have been treated for longer time periods 
with psychostimulant medication than in children where 
stimulant medication periods are typically shorter.
If the finding, based on the preliminary character of the 
present study, of normalization of reduced pain percep-
tion by MPH treatment in children can be replicated in 
further studies, it would have clinical/public health as 
well as scientific implications. It offers an important link 
to the observation that MPH treatment is associated with 
a reduced risk of injury-related emergency department 
admission in children and adolescents with ADHD [52]. 
It could be argued that their reduced pain perception as 
well as poor concentration and increased impulsivity may 
underlie the increased risk of injury-related emergency 
department admission.
We suggest that in addition to cognitive factors, 
including lower expectations of personal risk in hazard-
ous situations and less ability to generate prevention 
strategies and safety rules [53], reduced pain percep-
tion in children and adolescents with ADHD may also 
lead to higher risk tolerance by unfavorable effects on 
implicit learning as well as by misjudgments of danger-
ous situations. In view of the elevated rate of accident 
proneness [52, 54], a focus of ADHD behavioral treat-
ment programs on both, better concentration abilities 
and reduced impulsivity, but also on psychoeducation in 
terms of decreased pain perception might possibly help 
to minimize one of the negative consequences of ADHD, 
as for example the greater distress, the time in treatment 
and the caused expenses, in those children not treated 
with MPH. In addition, the positive effect of MPH treat-
ment on reduced accident proneness might be better 
understood by the modulation via changed pain percep-
tion. Therefore the present findings could be seen as a 
further piece of the puzzle to fully understand the patho-
physiology of ADHD.
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Limitations
Firstly, pain perception was not investigated using an 
experimental paradigm. The present data result from 
subjective questionnaires in which parents remembered 
painful events of their children and had to estimate the 
perceived severity of their children’s pain in the last 
3 months. Also older children and adolescents were asked 
to estimate their own pain perception. Analyses of both 
datasets together as well as separately showed reduced 
pain perception in children with ADHD without MPH 
medication in comparison to both, HC and children with 
MPH medication. However, it will be advantageous to 
conduct further research in order to add more depth to 
the question of whether ADHD and MPH are associated 
with altered pain perception in children and adolescents. 
In addition imaging studies analyzing neural correlates of 
theses alterations might provide further insights into the 
etiopathophysiological mechanisms underlying abnormal 
pain perception in ADHD and the mechanisms of action 
of MPH on normalizing this abnormal pain perception 
in ADHD. Moreover, although analyses with the SDQ 
item “hyperactivity” and the “ADHD diagnosis question” 
were shown to be highly correlated, we could not entirely 
control for the diagnostic validity. Finally common and 
distinct effects of frequent comorbidities in ADHD as 
well as differences in age and diagnosis systems have to 
be considered i.e. when designing future research in this 
field.
Conclusions
The present study found reports of reduced pain percep-
tion in children and adolescents with ADHD that seem 
to be normalized by MPH. If the suggested association 
between dopaminergic and potentially opioid deficits 
in the brain and altered pain perception could be shown 
experimentally in children and adolescents with ADHD, 
a further important step in the investigation of the patho-
physiology of ADHD would be reached. The role of MPH 
in this assumed interplay might be to regulate and thus 
to balance dopaminergic and potentially opioid deficits 
which in turn might lead to an enhancement of pain per-
ception up to the level of HC. Finally, not only in the con-
text of MPH treatment, but also of behavioral treatment 
programs for ADHD, attention to reduced pain percep-
tion might help to further minimize the increased risk for 
injuries and accidents in those children with ADHD not 
treated with MPH.
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